title: [The effectiveness of adjuvant systemic therapy in organ-preserving therapy of breast cancer].
abstract: The role of adjuvant therapy in breast-conserving treatment was studied in 360 cancer patients (reproductive, aged < or = 55 yrs, and postmenopausal, aged > 55 yrs) with T1-2N0M0 tumors under 2.5 cm (1985-1996). Mortality rates fell by 17% in postmenopausal patients who received adjuvant therapy (tamoxifen) and by 34%--in the reproductive group after polychemotherapy (CMF) and 36%--after hormonal therapy (tamoxifen).
authors.affiliation: Prof. N.N. Petrov Research Institute of Oncology, Health Ministry of the RF, St. Petersburg.
authors.forename: V F
authors.initials: VF
authors.lastname: Semiglazov
authors.forename: S V
authors.initials: SV
authors.lastname: Kanaev
authors.forename: I L
authors.initials: IL
authors.lastname: Bugrova
authors.forename: O L
authors.initials: OL
authors.lastname: Chagunava
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009367:Neoplasm Staging; D017698:Postmenopause; D017697:Premenopause; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen